Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976872 | 0.76 | CYP11B1 (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL9976819 | 0.75 | CYP11B1 (0.40) | CYP11B1CYP11B2MEN1TP53CYP3A4 | |
| SCHEMBL9976873 | 0.74 | CYP11B1 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL9976817 | 0.73 | CYP11B1 (0.39) | CYP11B1CYP11B2MEN1TP53CYP3A4 | |
| SCHEMBL9976865 | 0.72 | CYP11B1 (0.35) | CYP11B1CYP11B2MEN1TP53MAPT | |
| SCHEMBL9976831 | 0.71 | CYP11B1 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL9976828 | 0.71 | NAAA (0.39) | MEN1ALOX15MAPK1KMT2A | |
| SCHEMBL9976864 | 0.70 | NAAA (0.41) | MEN1MAPK1KMT2A | |
| SCHEMBL9976874 | 0.69 | CYP11B1 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL12841188 | 0.68 | CYP11B1 (0.36) | CYP11B1CYP11B2MEN1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680296-B2 | Leaving substituent-containing compound, products produced using the same, and methods for producing the products | RICOH COMPANY, LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-8680296-B2 | Leaving substituent-containing compound, products produced using the same, and methods for producing the products | RICOH COMPANY, LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20120153271-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | RICOH COMPANY, LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20120153271-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | RICOH COMPANY, LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120153271-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | F12, C1S, PYM1 | CYP11B1 1585/4885CYP11B2 1300/4885MEN1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.